Home    Back

Tl011, anti cd20, for the treatment of rheumatoid arthritis    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
46Malignant rheumatoid arthritis1

46. Malignant rheumatoid arthritis    [ 4,183 clinical trials,   2,538 drugs,   (DrugBank: 401 drugs),   183 drug target genes,   219 drug target pathways]
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 4,183 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT01123070
(ClinicalTrials.gov)		February 201011/5/2010TL011 in Severe, Active Rheumatoid Arthritis PatientsRheumatoid ArthritisBiological: TL011, anti CD20, for the treatment of rheumatoid arthritis;Biological: MabThera infusionsTeva Pharmaceutical IndustriesNULLCompleted18 Years80 YearsBoth48Phase 1;Phase 2Czech Republic;Hungary;Italy;Spain;United Kingdom;Germany